Decreased dolutegravir and efavirenz concentrations with preserved virological suppression in patients with TB and HIV receiving high-dose rifampicin.

Christine Sekaggya-WiltshireRuth NabisereJoseph MusaaziBrian OtaaloFlorence AberLucy AlinaitweJuliet NampalaLetisha NajjembaAllan BuzibyeDenis OmaliKamunkhwala GausiAllan KengoMohammed LamordeRob AarnoutsePaolo DentiKelly E DooleyDerek J Sloan

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

Compared to standard-dose rifampicin, high-dose rifampicin reduced dolutegravir and efavirenz exposures but HIV suppression was similar across treatment arms. Higher-dose rifampicin was well-tolerated among people living with HIV, and associated with a trend towards faster sputum culture conversion.

Keyphrases

antiretroviral therapy
mycobacterium tuberculosis
high dose
hiv infected
pulmonary tuberculosis
hiv infected patients
hiv positive
human immunodeficiency virus
hiv aids
low dose
stem cell transplantation
hiv testing
replacement therapy
men who have sex with men